Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease

Ruzicka, Marcel; Burns, Kevin D.; Hiremath, Swapnil

doi:10.1016/j.cjca.2017.01.007

Cited by 7 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 39 Participants randomized to “brachial cuff BP” will be treated to achieve a brachial cuff SBP < 130 mm Hg, as recommended by the American Heart Association for all patients with advanced CKD. 43 In advanced CKD, Hypertension Canada recommends either <130 mm Hg (diabetes) or <140 mm Hg (without diabetes), 46 both of which are based on non-standardized measurements, which yield SBP values 5 to 10 mm Hg higher than standardized measurements 61 (as will be used in this trial). Meeting the KDIGO target of <120 mm Hg, 10 as suggested in selected patients, will be at the discretion of the attending nephrologist.…”

Section: Methodsmentioning

confidence: 99%

CENtral blood pressure Targeting: a pragmatic RAndomized triaL in advanced Chronic Kidney Disease (CENTRAL-CKD): A Clinical Research Protocol

Goupil

Nadeau‐Fredette

Prasad

et al. 2023

Can J Kidney Health Dis

View full text Add to dashboard Cite

Background: Emerging data favor central blood pressure (BP) over brachial cuff BP to predict cardiovascular and kidney events, as central BP more closely relates to the true aortic BP. Considering that patients with advanced chronic kidney disease (CKD) are at high cardiovascular risk and can have unreliable brachial cuff BP measurements (due to high arterial stiffness), this population could benefit the most from hypertension management using central BP measurements. Objective: To assess the feasibility and efficacy of targeting central BP as opposed to brachial BP in patients with CKD G4-5. Design: Pragmatic multicentre double-blinded randomized controlled pilot trial. Setting: Seven large academic advanced kidney care clinics across Canada. Patients: A total of 116 adults with CKD G4-5 (estimated glomerular filtration rate [eGFR] < 30 mL/min) and brachial cuff systolic BP between 120 and 160 mm Hg. The key exclusion criteria are 1) ≥ 5 BP drugs, 2) recent acute kidney injury, myocardial infarction, stroke, heart failure or injurious fall, 3) previous kidney replacement therapy. Methods: Double-blind randomization to a central or a brachial cuff systolic BP target (both < 130 mm Hg) as measured by a validated central BP device. The study duration is 12 months with follow-up visits every 2 to 4 months, based on local practice. All other aspects of CKD management are at the discretion of the attending nephrologist. Outcomes: Primary Feasibility: Feasibility of a large-scale trial based on predefined components. Primary Efficacy: Carotid-femoral pulse wave velocity at 12 months. Others: Efficacy (eGFR decline, albuminuria, BP drugs, and quality of life); Events (major adverse cardiovascular events, CKD progression, hospitalization, mortality); Safety (low BP events and acute kidney injury). Limitations: May be challenging to distinguish whether central BP is truly different from brachial BP to the point of significantly influencing treatment decisions. Therapeutic inertia may be a barrier to successfully completing a randomized trial in a population of CKD G4-5. These 2 aspects will be evaluated in the feasibility assessment of the trial. Conclusion: This is the first trial to evaluate the feasibility and efficacy of using central BP to manage hypertension in advanced CKD, paving the way to a future large-scale trial. Trial registration: clinicaltrials.gov (NCT05163158)

show abstract

Section: Methodsmentioning

confidence: 99%

CENtral blood pressure Targeting: a pragmatic RAndomized triaL in advanced Chronic Kidney Disease (CENTRAL-CKD): A Clinical Research Protocol

Goupil

Nadeau‐Fredette

Prasad

et al. 2023

Can J Kidney Health Dis

View full text Add to dashboard Cite

show abstract

“…Contributing factors include the small effect size of individual variants, population heterogeneity, population size, polypharmacy, a relative lack of major antihypertensive drug toxicities, varying clinical trial designs with relatively small patient populations, and the polygenic nature of antihypertensive drug response. Overcoming nonadherence to therapy [17], great inter- and intra-patient BP variability [18,19], and differences in BP measurement strategies [20,21] may be of equal or greater importance in improving clinical effectiveness than genotype-guided prescribing. Provider inertia is an additional barrier due to a lack of familiarity with pharmacogenomics [22,23].…”

Section: Introductionmentioning

confidence: 99%